TruCare
Oncology Billing Services

One missing modifier can
erase an oncology billing claim

A single chemotherapy vial can cost thousands of dollars. Medicare wants to know exactly how much was given and how much was discarded. Miss the modifier confirming zero waste, and the claim is erased entirely. Miss the one for real waste, and the practice absorbs a cost it was owed. Our oncology billing services get that distinction right, on every drug claim.
96%avg. net collection rate across TruCare clients
Woman in a yellow headscarf sitting in a hospital bed, looking out the window near equipment.
Female doctor in a white coat showing a laptop screen to a female patient wearing a head scarf.
Smiling older man with gray hair and glasses gesturing with both hands during a video call at a laptop.
See your numbers

Results across TruCare clients

96%
average net collection rate across TruCare clients
>95%
clean claim rate, accepted on first submission
−37%
fewer claim rejections
−38%
days in A/R
Figures reflect TruCare client results across specialties, trailing twelve months.

Why oncology practices choose our oncology medical billing services

Rated 4.8 / 5
Based on 180+ client reviews
Verified client reviews
May 06, 2027
We were missing JZ on claim after claim
We assumed no waste meant nothing to report. It turned out Medicare wants to see that confirmed explicitly, and we had been denied for months without understanding why.
Dr. Anand Krishnamurthy, medical oncologist
3 weeks ago
Our pathway compliance stopped slowing down treatment
We were losing days to authorization requests that could have been avoided if the regimen had been checked against the payer’s pathway first.
Simone Achterberg, practice administrator
Mar 18, 2027
340B billing finally matches current rules
We were still using an old modifier for our 340B-acquired drugs. Nobody had told us it had been retired.
Reginald Oyelaran, billing manager
Jan 29, 2027
Our clinical trial patients finally bill correctly
We had patients in trials and were billing their routine care the same as everyone else, without separating what the sponsor covers from what insurance should.
Dr. Felicity Nwosu, medical oncologist
Dec 11, 2026
One view across drugs, authorizations, and denials
Drug waste, authorization status, and denials used to live in three different places. Now it is one screen.
Harriet Okonkwo, revenue cycle director

What we handle, from authorization to the drug claim

View all services
We get your oncologists and your infusion staff enrolled
TruCred files Medicare, Medicaid, and commercial enrollments and keeps your records current. Revalidation dates are tracked so nothing lapses.
Provider enrollmentPECOS upkeepRevalidation
TruIntake
TruCred
TruRev
TruIntel
TruCare OS

The drug costs more than the visit. The modifier decides who pays for the difference.

In most specialties, the service is the expensive part and the supplies are incidental. Oncology runs the other way. A single vial of chemotherapy drug can cost thousands of dollars, and the actual physician service, the infusion itself, is comparatively small. That changes what the claim has to prove. Medicare does not just want to know a drug was given. It wants to know exactly how much was administered, how much was discarded, and whether any of it came through a discount program.
Miss the modifier confirming zero waste, and the claim is denied outright, treated as if the reporting itself was never done. Miss the modifier for actual waste, and the practice absorbs a cost that should have been reimbursed. Use an outdated program identifier instead of the current one, and the claim does not match what the payer’s system now expects.
Layered on top of that sits one of the heaviest prior authorization burdens in medicine. Many payers require a proposed regimen to match a specific, approved treatment pathway before they will authorize it at all, and treatment often cannot begin until that approval comes through.
A billing company unfamiliar with these specific, dollar-heavy reporting requirements will get the office visit right and lose real money on exactly the part of the claim that actually matters most.
Six places oncology revenue goes missing
The zero-waste modifier was left off
Medicare requires explicit confirmation that nothing was discarded from a single-dose vial. Leaving this off is treated as a reporting failure, not a minor omission, and the claim is denied.
Real waste was never reported
When a dose does not use the full vial, the discarded amount is separately billable. Not reporting it means the practice absorbs a cost Medicare would have paid.
An outdated 340B modifier was still in use
Program identifiers for discount-acquired drugs have changed. A claim using the retired version does not match current system requirements.
J-code units did not match the actual dose
Billing based on the vial size instead of what was actually administered creates a mismatch between the claim and the clinical record.
Treatment started before authorization was confirmed
Beginning an infusion before a pathway-dependent authorization comes through risks the entire claim, not just a portion of it.
Clinical trial routine costs were billed inconsistently
Billing a trial patient’s routine visits the same as a non-trial patient, without the coverage distinction that actually applies, creates both compliance risk and lost revenue.

Rated on the platforms that matter

Google rating 4.8 out of 5Trustpilot rating 4.8 out of 5BBB accredited business, A+ rating
Ratings shown are collected from verified client reviews.
Our service offerings

Every part of a modern oncology practice

Chemotherapy and infusion administration
Push, infusion, and sequential drug administration, billed by the correct hierarchy so the initial and additional services are sequenced the way payers expect.
High-cost drug billing
J-code billing matched to actual administered dose, with waste reporting handled on every applicable single-dose vial claim.
340B drug program billing
Drugs acquired through the discount program identified under current modifier requirements, kept distinct from standard-acquired drugs on the same claim.
Immunotherapy and targeted therapy
Newer treatment classes billed under their own specific codes and their own, often more demanding, authorization requirements.
Oral oncolytics
Medications billed through the pharmacy benefit rather than the medical benefit in many cases, coordinated with specialty pharmacy rather than treated as a standard buy-and-bill drug.
Prior authorization and pathway compliance
Regimens checked against payer-specific treatment pathways before authorization is requested, reducing the chance of a late denial after treatment has already started.
Clinical trial routine cost billing
Billing for the routine care portion of a qualifying clinical trial to insurance, separate from research-specific costs the trial sponsor is responsible for.
Radiation oncology, briefly
Treatment delivery billed under its own distinct code family, separate from the chemotherapy and infusion billing that makes up most of a medical oncology practice.

What actually makes this work

Billers who read the drug record, not just the order
Certified billers and coders on your account check actual administered dose against vial size before a drug claim is built, which is where most oncology denials and lost revenue actually start.
Authorization checked against the pathway before scheduling
We confirm a regimen’s pathway compliance and authorization status before the first infusion date is set, not after a denial arrives.
No disruption to how your infusion suite already runs
We work from the system your practice already uses. Nobody on your clinical staff learns a second one.

What actually causes oncology claims to fail

An oncology denial is rarely about whether treatment was necessary. It is almost always about whether a specific, dollar-sensitive reporting requirement, waste, program identification, or authorization, was met exactly as the payer expects.
Here is what we see most, and how each is caught before it becomes routine.
Curious what your denials are actually costing you?
Send us 90 days and we will show you the pattern.
Request a billing audit
The recurring six:
Smiling bald woman wrapped in a tan blanket, sitting in a sunlit hospital room.
Missing zero-waste confirmation
A single-dose vial claim with no waste reported and no explicit zero-waste modifier is treated as incomplete, not simply accurate.
Waste never separately reported
Discarded drug amounts that go unreported represent real, recoverable revenue that the practice never claims.
Outdated program modifier used
A retired identifier for discount-acquired drugs does not match what current claims processing expects.
Dose and billed units mismatched
Billing the vial size rather than the actual administered amount creates a discrepancy between the claim and the medical record.
Treatment started without confirmed authorization
Beginning a pathway-dependent regimen before approval is finalized puts the entire claim at risk.
Clinical trial billing not separated correctly
Billing routine trial-related care without distinguishing it from standard care, or without applying the correct coverage rule, creates both a compliance and a revenue problem.

The details that decide whether a drug claim actually pays

Our oncology billing and coding services run on a small number of modifiers that carry an outsized financial consequence. Getting the drug code right matters far less than getting the waste reporting and the program identification exactly right, since that is where this specialty’s real money sits.
Walk through your coding with us
The ones that matter most:
96401–96549
Chemotherapy and infusion administration
Billed by route and complexity, push versus infusion, with specific sequencing rules for an initial service versus additional or sequential drugs in the same encounter. These codes have not changed structurally in recent years.

We connect to the EHR you already use

An oncology practice documents drug administration, dosing, and authorization status through its own system, and we do not ask that to change. Whether your practice runs on Epic, iKnowMed, or Flatiron OncoEMR, TruCare pulls from whatever platform your infusion suite and your office already use.
What changes is what gets caught before it becomes a denial. A single-dose vial claim about to go out with no waste modifier at all. A 340B drug about to be billed under a retired identifier. A regimen about to start before its pathway authorization has actually cleared. Each one surfaces while it can still be corrected.
Check for your system
Doctor’s hands holding a red awareness ribbon, with a white logo in the corner.

Deep integrations with all EHRs

TruCare connects seamlessly with your existing workflows — no switching required.

Epic
MEDITECH
Cerner
athenahealth
EXPERITY
eClinicalWorks
AdvancedMD
Kareo
WebPT
Axxess
inSync
Epic
MEDITECH
Cerner
athenahealth
EXPERITY
eClinicalWorks
AdvancedMD
Kareo
WebPT
Axxess
inSync
Epic
MEDITECH
Cerner
athenahealth
EXPERITY
eClinicalWorks
AdvancedMD
Kareo
WebPT
Axxess
inSync
Clinicient
Altera Digital Health
Cerbo
hellonote
Jane
Nexus Clinical
drchrono
HealthCare Synergy
Office Ally
Elation
Lightning Step
Clinicient
Altera Digital Health
Cerbo
hellonote
Jane
Nexus Clinical
drchrono
HealthCare Synergy
Office Ally
Elation
Lightning Step
Clinicient
Altera Digital Health
Cerbo
hellonote
Jane
Nexus Clinical
drchrono
HealthCare Synergy
Office Ally
Elation
Lightning Step

What actually moved for this specialty this year

Chemotherapy administration codes did not change
The underlying CPT code structure for chemotherapy and infusion administration remained the same for 2026. Anything claiming new administration codes this year is describing something that did not happen.
Site-neutral payment expanded to drug administration
CMS finalized an expansion of its site-neutral payment policy to cover drug administration services furnished in excepted off-campus, provider-based departments, directly affecting hospital-affiliated oncology practices.
Radiation treatment delivery codes were consolidated
Three codes, 77385, 77386, and 77014, were deleted and consolidated into 77402, 77407, and 77412, a structural change specific to radiation oncology billing.
The 340B identification modifier changed before this year, and confusion still lingers
The modifier once used to flag 340B-acquired drugs was discontinued effective January 1, 2025, replaced entirely by the current identifier, though some billing guidance still incorrectly references the retired version.
Skin substitutes were reclassified, removing them from waste reporting entirely
Effective January 1, 2026, non-biologic skin substitutes were reclassified as incident-to supplies rather than drugs, meaning JW and JZ reporting no longer applies to them at all.
JZ enforcement continued to generate denials for practices that overlook it
Mandatory since mid-2023, the zero-waste modifier continues to be one of the single most common sources of avoidable denials for practices still adjusting their workflow around it.

Someone has to track a modifier system this precise

A reporting requirement this specific, applied to drugs this expensive, is not something to leave to habit or memory.

We track every change to waste reporting and program identification rules, and we build each one into how your claims are checked before they go out.
In-house vs. outsourced

What one biller cannot track on claims this expensive

A general biller can learn standard drug billing reasonably well. Tracking exact waste reporting on every single-dose vial, keeping 340B identification current, and confirming pathway authorization before treatment starts is a different, much higher-stakes kind of attention. Outsourcing oncology billing services puts people on this who treat every drug claim with that level of precision.
The questionOne in-house billerTruCare
Waste reportingInconsistent or skippedApplied correctly on every single-dose vial claim
340B identificationSometimes using an outdated modifierAlways current
Dose versus billed unitsVial size billed by habitMatched to actual administered dose
Prior authorization and pathwaysRequested after schedulingConfirmed before treatment begins
Clinical trial billingBilled the same as standard careSeparated correctly by coverage rule
Radiation oncology codingLearned as claims failCurrent with the latest code consolidation
Cost shapeSalary, benefits, training, softwareA percentage of collections, so it scales with volume
Staff absenceBilling slows on high-dollar claimsCoverage is handled without disruption
Regulatory changeDiscovered through a denialTracked and built into process ahead of time
VisibilityA report assembled on requestLive, by drug, by modifier, and by regimen
Compare against your numbersCurious where your practice actually stands? Send us 90 days of denials and aging A/R.
Hover a state to see coverage
Where we serve

Oncology billing in every state

We work with medical oncology practices, cancer centers, and combined hematology-oncology groups. As a cancer center billing services provider, we apply the same precision to waste reporting and authorization on every claim, regardless of how large or how specialized your practice is.
Drug waste reporting
340B billing
Prior authorization and pathways
Clinical trial billing
Multi-state enrollment
A named account contact
Who we bill every day
Medicare Part B
Drug billing, waste reporting, and the 2026 payment changes
Medicare Advantage
Authorization and pathway requirements that are often stricter than traditional Medicare
Medicaid and managed Medicaid
State programs and MCO plans
BCBS and Anthem
Pathway compliance programs that vary by plan
Centene family
Molina, WellCare, Amerigroup
Other
Self-pay and clinical trial sponsor coordination
We bill whatever plans your practice is contracted with. If you are not contracted yet, TruCred handles the enrollment.

Oncology billing saver guide

A practice collecting $2.05 million saves up to $22,015 a year by outsourcing to TruCare
In-house billingWith TruCareAnnual saving
Dedicated billing staff$73,060$0$73,060
Billing software and clearinghouseVariesIncluded—
Training, turnover, and coverageVariesIncluded—
TruCare fee (from 2.49% of collections)—$51,045—
Total annual cost$73,060$51,045$22,015
Example: a practice collecting $2.05 million a year with one full-time biller, at TruCare’s starting rate of 2.49%. Biller cost uses the BLS May 2025 median wage for medical records specialists ($51,140), with benefits at 30% of total compensation. Software and training costs vary by practice and are not counted. We do not replace your front desk, we take the claims work off it. Larger oncology practices, where collections are driven heavily by high-cost drug volume, are quoted on volume rather than at the starting rate, so a bigger practice should not scale this example up.
Want this run on your own numbers?
Talk to an oncology billing expert

What a practice gains once every modifier is actually checked

“We assumed our denials were about the drugs themselves being questioned. They were not. They were about a reporting requirement we did not fully understand, applied to drugs expensive enough that the mistake was never small. Once someone actually fixed how we reported waste, the difference showed up immediately.”
Dr. Anand Krishnamurthy
Medical oncologist, community oncology practice

We use cookies to understand how visitors use our site and to improve your experience. You can accept or decline analytics cookies. See our Privacy Policy for details.